Contact
searchSearch
HMP Global

News

News
Bimekizumab is Safe and Effective in Treating Patients With Psoriatic Arthritis Native to Biologic Treatment, Study Finds
11/15/2023
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
Examining Barriers to Biosimilar Adoption in Clinical Practice
11/14/2023
This research summary explores the experiences and perspectives of academic clinicians on increasing biosimilar adoption, emphasizing the need for education and systemic changes in pricing and reimbursement to improve acceptance among...
This research summary explores the experiences and perspectives of academic clinicians on increasing biosimilar adoption, emphasizing the need for education and systemic changes in pricing and reimbursement to improve acceptance among...
This research summary explores...
11/14/2023
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Patients With MS Switching to Teriflunomide: Characteristics, Utilization, and Relapses
11/09/2023
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from...
11/09/2023
First Report Managed Care
News
FeNO Suppression Testing Cost Effective for Detecting Nonadherence in Difficult-to-Control Asthma
11/09/2023
Fractional exhaled nitric oxide (FeNO) suppression testing (FeNOSuppT), as a screening tool before biologic therapy in difficult-to-control asthma cases, demonstrated cost savings of $4435 per patient over 1 year and was deemed cost-effective...
Fractional exhaled nitric oxide (FeNO) suppression testing (FeNOSuppT), as a screening tool before biologic therapy in difficult-to-control asthma cases, demonstrated cost savings of $4435 per patient over 1 year and was deemed cost-effective...
Fractional exhaled nitric oxide...
11/09/2023
First Report Managed Care
News
The Role of Fungi in Allergic Disease and the Evolutionary Advantage of Type 2 Immune Response
11/07/2023
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the...
11/07/2023
First Report Managed Care
News
Dazdotuftide Offers Potential for Diabetic Retinopathy, Macular Degeneration Treatment
11/07/2023
Dazdotuftide, a novel multi-target drug, offers promising potential for the treatment of diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD).
Dazdotuftide, a novel multi-target drug, offers promising potential for the treatment of diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD).
Dazdotuftide, a novel...
11/07/2023
First Report Managed Care
News
High Rates of Therapy Switching Among Patients With Psoriasis Initiating Biologics
11/06/2023
“Switching was common in psoriasis patients using biologics over 24 months, with the lowest risk of switching observed with IL-23 inhibitors,” said researchers. 
“Switching was common in psoriasis patients using biologics over 24 months, with the lowest risk of switching observed with IL-23 inhibitors,” said researchers. 
“Switching was common in...
11/06/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care

Behind the Bill

Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations 2.0: New Administration, Same Mission?
01/22/2025
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major...
01/22/2025
First Report Managed Care
Behind the Bill
The First 100 Days: Health Care's Critical Deadlines in 2025
01/15/2025
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces...
01/15/2025
First Report Managed Care
Behind the Bill
Trump's Executive Orders in a Post-Chevron World: Implications for Health Care Policy
01/08/2025
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into...
01/08/2025
First Report Managed Care
Behind the Bill
A Tale of Two Congresses—Health Care Policy in the 117th vs 118th
12/18/2024
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping...
12/18/2024
First Report Managed Care
Behind the Bill
Medicare Privatization Under New CMS Leadership: What's Really at Stake
12/11/2024
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's...
12/11/2024
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations Under New CMS Leadership
12/04/2024
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump...
12/04/2024
First Report Managed Care
Behind the Bill

When Recess Isn’t a Break: What NLRB v Canning Means for HHS
11/20/2024
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s...
11/20/2024
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use